National

The daily dose: October 5, 2021

Our Bureau October 5 | Updated on October 05, 2021

A health worker administers a dose of Covid-19 vaccine to a beneficiary, at Government Polyclinic vaccination centre in Gurugram   -  PTI

We curate some of the top Covid stories for you

# Drone drop: Ten people would receive their first dose and eight their second at a Primary Health Centre in a far-flung location in Manipur, where vaccines were dropped off by a drone, the Health Minister said, launching ICMR’s drone initiative.

https://www.thehindubusinessline.com/news/national/icmrs-drone-based-vaccine-delivery-model-in-n-e-takes-off/article36829213.ece

# Compensation cleared: The Supreme Court has said, no State should deny the ex-gratia compensation of ₹50,000, as recommended by National Disaster Management Authority (NDMA), to the kin of persons who died of Covid-19 on the sole ground that death certificate does not mention it as the cause of death.

https://www.thehindubusinessline.com/news/national/no-state-should-deny-50000-ex-gratia-to-kin-of-those-who-lost-lives-to-covid-19-sc/article36818262.ece

# “Party plot” garba, replaced by humble street-corner ones: Despite the low daily Covid case count, the Gujarat government is not taking chances, and has put strict restrictions on gatherings.

https://www.thehindubusinessline.com/news/national/no-navratri-waltz-for-gujarat-as-state-curbs-garbas/article36828655.ece?homepage=true

#Kerala’s diagnostic prices stay, for now: The Kerala High Court set aside the State government’s order reducing the price of RT-PCR tests from ₹1,700 to ₹500 in private diagnostic labs in the State.

https://www.thehindubusinessline.com/news/national/kerala-hc-sets-aside-slashing-of-rt-pcr-test-charges/article36828363.ece

# Go-ahead to the two dose vaccine trial: After getting an Emergency Use Authorization for its three-dose Covid-19 vaccine ZyCov-D, Cadila Healthcare Limited ( Zydus Cadila) has received a go-ahead for phase-III trials for its two-dose regimen.

https://www.thehindubusinessline.com/companies/dcgi-approves-phase-3-trial-of-zydus-two-dose-vaccine/article36829607.ece

# Race for molnupiravir: Close to a dozen companies in India are in the race to make anti-viral drug molnupiravir, the oral drug from Merck, that recently showed promising results in reducing Covid-19 linked hospitalisations and halving deaths in those at risk.

https://www.thehindubusinessline.com/news/mercks-promising-results-fuel-expectations-for-indian-partners/article36829561.ece

# Schools reopen: After a year-and-a-half, physical classes in schools across Maharashtra resumed on Monday. https://www.thehindubusinessline.com/news/after-18-months-schools-reopen-across-maharashtra-for-physical-classes/article36816922.ece

# Also in Maharashtra: About 61 Villages in Ahmednagar will be shutdown for 10 days starting Monday. https://www.thehindubusinessline.com/todays-paper/tp-others/tp-variety/article36832631.ece

# Pandemic drop in aviation to lose $201 billion between 2020-22: The global aviation industry will lose $201 billion between 2020 and 2022 due to the Covid-19 crisis before returning to profitability in 2023.

https://www.thehindubusinessline.com/economy/logistics/covid-19-crisis-global-aviation-industry-may-return-to-profitability-in-2023/article36833745.ece?homepage=true

# Australia no-go: International tourists won’t be welcomed back to Australia until next year, with the return of skilled migrants and students given higher priority, their Prime Minister said.

https://www.thehindubusinessline.com/news/world/australia-wont-welcome-international-tourists-until-2022/article36834018.ece

# Visually, September wanes: Intensity of Covid-19 wanes in September. https://www.thehindubusinessline.com/data-stories/visually/intensity-of-covid-19-wanes-in-september/article36829754.ece

Published on October 05, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.

You May Also Like